vs
Side-by-side financial comparison of ACME UNITED CORP (ACU) and Adaptive Biotechnologies Corp (ADPT). Click either name above to swap in a different company.
Adaptive Biotechnologies Corp is the larger business by last-quarter revenue ($70.9M vs $52.3M, roughly 1.4× ACME UNITED CORP). Adaptive Biotechnologies Corp runs the higher net margin — 4.7% vs 1.9%, a 2.9% gap on every dollar of revenue. On growth, Adaptive Biotechnologies Corp posted the faster year-over-year revenue change (35.1% vs 13.8%). Over the past eight quarters, Adaptive Biotechnologies Corp's revenue compounded faster (28.1% CAGR vs -2.9%).
Acme United Corporation is a supplier of cutting, measuring and safety products for the school, home, office, hardware and industrial markets. The company was organized as a partnership in 1867 and incorporated in 1873 under the laws of the State of Connecticut. It is publicly traded on the NYSE American with symbol ACU.
ExpreS2ion Biotechnologies is a Danish biotechnology company specialised in the development of new vaccines and immunotherapy products based in Hørsholm, Denmark and listed on the Nasdaq First North Growth Market Sweden.
ACU vs ADPT — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $52.3M | $70.9M |
| Net Profit | $985.0K | $3.4M |
| Gross Margin | 39.7% | 73.6% |
| Operating Margin | 3.3% | -27.1% |
| Net Margin | 1.9% | 4.7% |
| Revenue YoY | 13.8% | 35.1% |
| Net Profit YoY | -40.4% | — |
| EPS (diluted) | $0.24 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $52.3M | $70.9M | ||
| Q4 25 | $47.5M | $71.7M | ||
| Q3 25 | $49.1M | $94.0M | ||
| Q2 25 | $54.0M | $58.9M | ||
| Q1 25 | $46.0M | $52.4M | ||
| Q4 24 | $45.9M | $47.5M | ||
| Q3 24 | $48.2M | $46.4M | ||
| Q2 24 | $55.4M | $43.2M |
| Q1 26 | $985.0K | $3.4M | ||
| Q4 25 | $1.9M | $-13.6M | ||
| Q3 25 | $1.9M | $9.5M | ||
| Q2 25 | $4.8M | $-25.6M | ||
| Q1 25 | $1.7M | $-29.9M | ||
| Q4 24 | $1.7M | $-33.7M | ||
| Q3 24 | $2.2M | $-32.1M | ||
| Q2 24 | $4.5M | $-46.2M |
| Q1 26 | 39.7% | 73.6% | ||
| Q4 25 | 38.2% | 74.6% | ||
| Q3 25 | 39.1% | 80.7% | ||
| Q2 25 | 41.0% | 69.4% | ||
| Q1 25 | 39.0% | 67.6% | ||
| Q4 24 | 38.7% | 62.0% | ||
| Q3 24 | 38.5% | 64.1% | ||
| Q2 24 | 40.8% | 55.3% |
| Q1 26 | 3.3% | -27.1% | ||
| Q4 25 | 6.1% | -17.8% | ||
| Q3 25 | 6.1% | 10.9% | ||
| Q2 25 | 11.8% | -42.5% | ||
| Q1 25 | 5.3% | -56.4% | ||
| Q4 24 | 5.0% | -71.3% | ||
| Q3 24 | 6.1% | -70.3% | ||
| Q2 24 | 11.5% | -109.6% |
| Q1 26 | 1.9% | 4.7% | ||
| Q4 25 | 3.9% | -18.9% | ||
| Q3 25 | 3.9% | 10.2% | ||
| Q2 25 | 8.8% | -43.5% | ||
| Q1 25 | 3.6% | -56.9% | ||
| Q4 24 | 3.7% | -71.0% | ||
| Q3 24 | 4.6% | -69.1% | ||
| Q2 24 | 8.0% | -107.0% |
| Q1 26 | $0.24 | — | ||
| Q4 25 | $0.46 | $-0.08 | ||
| Q3 25 | $0.46 | $0.06 | ||
| Q2 25 | $1.16 | $-0.17 | ||
| Q1 25 | $0.41 | $-0.20 | ||
| Q4 24 | $0.43 | $-0.22 | ||
| Q3 24 | $0.54 | $-0.22 | ||
| Q2 24 | $1.09 | $-0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.2M | $77.6M |
| Total DebtLower is stronger | $33.0M | — |
| Stockholders' EquityBook value | $116.7M | — |
| Total Assets | $195.2M | $505.9M |
| Debt / EquityLower = less leverage | 0.28× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $4.2M | $77.6M | ||
| Q4 25 | $3.6M | $70.5M | ||
| Q3 25 | $5.1M | $55.0M | ||
| Q2 25 | $3.6M | $43.2M | ||
| Q1 25 | $3.4M | $50.6M | ||
| Q4 24 | $6.4M | $47.9M | ||
| Q3 24 | $5.7M | $38.1M | ||
| Q2 24 | $3.8M | $59.8M |
| Q1 26 | $33.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $116.7M | — | ||
| Q4 25 | $117.6M | $218.8M | ||
| Q3 25 | $115.8M | $204.4M | ||
| Q2 25 | $113.7M | $179.7M | ||
| Q1 25 | $108.3M | $190.4M | ||
| Q4 24 | $107.0M | $202.7M | ||
| Q3 24 | $106.3M | $223.8M | ||
| Q2 24 | $104.0M | $241.6M |
| Q1 26 | $195.2M | $505.9M | ||
| Q4 25 | $171.0M | $512.7M | ||
| Q3 25 | $173.0M | $490.6M | ||
| Q2 25 | $170.9M | $496.6M | ||
| Q1 25 | $163.0M | $510.9M | ||
| Q4 24 | $162.2M | $539.4M | ||
| Q3 24 | $165.5M | $558.5M | ||
| Q2 24 | $173.5M | $584.9M |
| Q1 26 | 0.28× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
